Our PNA Gene Targeting Service supports biotech companies, pharmaceutical discovery teams, CROs, and research institutions developing sequence-specific peptide nucleic acid constructs for gene modulation studies. PNA is a synthetic nucleic acid analog with a neutral polyamide backbone that enables strong and selective binding to complementary DNA or RNA targets, making it highly useful for antigene design, antisense blocking, splice modulation, mutation-selective targeting, and locus-focused functional studies. Successful PNA gene targeting projects depend on much more than sequence matching alone. Target accessibility, hybridization mode, mismatch discrimination, solubility, intracellular delivery, and assay design all influence whether a candidate performs as intended.
Our platform combines target review, custom PNA design, synthesis, conjugation planning, analytical characterization, and research-stage validation support to help teams move from a gene hypothesis to workable PNA constructs. Whether your project involves promoter-targeting antigene PNA, splice-switching PNA, transcript-blocking PNA, or exploratory donor-assisted genome targeting concepts, we provide a structured service workflow aligned with discovery efficiency, technical reproducibility, and decision-ready data. For broader platform support, clients may also explore our PNA technology services.
Choosing the Right Targeting Level: Many projects begin with a gene of interest but not a clear intervention strategy. Some questions are best addressed by targeting genomic DNA near promoters or regulatory loci, while others require transcript-level blocking or splice-junction targeting. We help define whether antigene, antisense, splice-switching, or hybrid strategies are the most workable fit for the biological objective and readout plan.
Finding Targetable Regions: PNA binding strength does not automatically guarantee useful gene targeting performance. Target region accessibility, local sequence context, mismatch position, transcript isoforms, and locus architecture can all affect outcome. We review candidate regions so clients avoid spending time on sequences that look plausible in silico but are difficult to validate experimentally.
Managing Delivery Constraints: For cell-based gene targeting studies, uptake and intracellular localization often become the limiting step. DNA-directed antigene projects may require efficient nuclear access, while RNA-directed projects may need a different delivery logic. Our drug delivery system capabilities support research-stage evaluation of peptide, lipid, polymer, and nanoparticle-compatible approaches for PNA programs.
Controlling Construct Behavior: Sequence length, base composition, terminal modifications, linker selection, and conjugated payloads can all change PNA solubility, purification difficulty, and hybridization behavior. We design fit-for-purpose constructs that balance targeting intent with synthesis feasibility, handling properties, and downstream assay compatibility.
Generating Decision-Ready Data: Gene targeting programs often stall when teams receive material without enough context on design rationale, purity profile, or screening logic. We structure projects around candidate comparison, analytical confirmation, and reporting packages so discovery groups can make practical next-step decisions with greater confidence.
Our PNA gene targeting service is designed for organizations that need coordinated support across target review, sequence engineering, synthesis, modification, delivery planning, and functional evaluation. We support research-stage programs focused on gene regulation, genomic locus interrogation, transcript blocking, splice control, and mutation-selective targeting.
By integrating design logic with practical chemistry and application planning, we help reduce rework, shorten candidate triage cycles, and deliver PNA constructs that are more likely to fit the intended assay or model system.
This table helps project teams compare the main PNA gene targeting formats by target level, research objective, design focus, and common implementation risks.
| Targeting Format | Primary Target Level | Typical Research Goal | Core Design Focus | Main Watchpoints |
| Promoter-Blocking Antigene PNA | Genomic DNA near promoter or transcription start region | Interfere with transcription initiation or probe promoter function | Locus accessibility, mismatch selectivity, nuclear delivery, construct stability | Difficult genomic access, sequence-context dependence, cell delivery limitations |
| Gene Body Antigene PNA | Genomic DNA within intronic or coding regions | Study locus-specific binding and DNA-level gene regulation mechanisms | Binding mode, target architecture, sequence compatibility, assay design | Variable invasion behavior, readout complexity, target-site dependency |
| Antisense PNA | Mature mRNA | Block translation or interfere with transcript-level function | Transcript region choice, isoform mapping, mismatch placement, cytosolic access | Transcript structure effects, uptake limitations, sequence-dependent performance |
| Splice-Switching PNA | Pre-mRNA splice junction or regulatory splice region | Redirect exon inclusion, exon skipping, or isoform balance | Junction selection, nuclear localization, timing of assay readout | Narrow target window, delivery burden, variable splice response by cell model |
| Mutation-Selective PNA | DNA or RNA containing a sequence variant | Distinguish mutant and matched wild-type sequences in research studies | Mismatch position, duplex stability window, allele discrimination strategy | Reduced selectivity if mismatch placement is suboptimal, assay-condition sensitivity |
| γPNA or Donor-Assisted Design | Genomic DNA plus donor sequence in exploratory editing workflows | Evaluate feasibility of site-directed sequence correction or genome interaction studies | Modified backbone choice, donor compatibility, delivery system, detection plan | High delivery complexity, workflow sensitivity, need for carefully defined readouts |
Effective PNA gene targeting programs depend on early review of target biology, construct chemistry, delivery burden, and validation requirements. The matrix below summarizes the main factors we assess before finalizing a build plan.
| Design Factor | Why It Matters | What We Review | Impact on Service Plan | Typical Output |
| Target Level | DNA-, pre-mRNA-, and mRNA-directed projects require different design and delivery logic | Biological objective, readout type, assay model, target compartment | Determines whether antigene, antisense, splice-switching, or hybrid strategy is prioritized | Strategy recommendation and candidate framework |
| Region Accessibility | Some apparent sequence matches are difficult to exploit experimentally | Locus context, transcript context, local sequence characteristics, competing sites | Shapes candidate ranking and screening panel breadth | Prioritized target regions |
| Sequence Composition | Length and base balance influence affinity, specificity, and handling behavior | Candidate size, GC balance, repeat content, mismatch position | Guides sequence refinement and control design | Finalized construct set |
| Solubility Profile | Poorly behaving constructs can delay purification, formulation, and assay setup | Hydrophobicity drivers, sequence-dependent aggregation risk, terminal group effects | May require linker adjustment, reformulation planning, or conjugate redesign | Handling and buffer recommendations |
| Functionalization Need | Delivery, detection, or capture often depends on added chemical functionality | Fluorophore, peptide, PEG, lipid, biotin, spacer, or immobilization requirements | Defines conjugation strategy and analytical scope | Modified PNA construct plan |
| Delivery Burden | Many gene targeting studies fail at the uptake or localization stage rather than at sequence design | Cell type, target compartment, dosing window, construct format | Informs feasibility assessment and delivery workflow selection | Delivery evaluation roadmap |
| Validation Scope | Different projects need different levels of chemistry and functional confirmation | QC expectations, candidate count, screening depth, reporting needs | Aligns the project with synthesis, analysis, and comparative testing steps | QC package and reporting format |
| Next-Step Decision Path | Discovery teams need clear outputs for progression or redesign | Internal milestone criteria, follow-on biology work, scale-up intent | Helps define whether the project should emphasize screening, optimization, or reproducible rebuilds | Actionable recommendation summary |
Our workflow is structured for research-stage gene targeting programs that require practical coordination between target biology, PNA chemistry, validation planning, and delivery considerations.
We review the gene of interest, target sequence information, species, transcript or locus context, experimental model, and desired outcome. This step clarifies whether the project is aimed at promoter interference, transcript blocking, splice modulation, mutation-selective targeting, or exploratory genome-targeting work.
Our team evaluates targetability, candidate region logic, expected delivery burden, and readout suitability. We then recommend the most appropriate PNA targeting strategy and define the candidate breadth needed for efficient discovery-stage testing.
Final sequence architecture, controls, terminal groups, linker options, and optional modifications are confirmed. For more complex programs, this phase may also include screening-panel design, conjugation decisions, and assay-oriented build recommendations.
We synthesize the agreed PNA constructs, apply the required purification strategy, and perform identity and purity checks suitable for the program scope. Modified or conjugated constructs are processed with attention to structural integrity and downstream usability.
When included, candidate sequences move into comparative screening, hybridization review, or delivery-feasibility planning. This step helps clients distinguish strong candidates from sequences that bind in principle but are less practical in the chosen assay or model system.
We deliver the project package with construct details, analytical results, and any agreed screening observations or technical recommendations. The final handoff is designed to support internal decision-making, follow-on biology work, or the next optimization cycle.
We built this service for clients who need more than basic custom synthesis. Gene targeting projects require coordinated judgment across biology, chemistry, delivery, and assay execution, and our workflow is designed to address those variables in a commercially practical way.
Our service supports research and development programs where precise sequence recognition is needed to interrogate gene function, compare targeting strategies, or build more application-ready PNA constructs for discovery workflows.
From early target review to custom construct delivery, our PNA Gene Targeting Service is built to help research teams develop workable antigene, antisense, splice-switching, and locus-directed PNA strategies with greater technical clarity. We support discovery organizations that need thoughtful sequence design, reliable synthesis, modification flexibility, delivery-aware planning, and documentation that can be used for internal decision-making. Whether you need a small candidate panel, a conjugated construct, or a broader gene targeting workflow linked to screening and analytical review, our team can help define the right service scope for your program. Contact us to discuss your target gene, construct requirements, and project goals.
It is a research service focused on designing and producing PNA constructs that bind specific DNA or RNA targets for gene regulation, splice modulation, or locus-focused studies.
Yes. Depending on project goals, PNA can be designed for genomic DNA-directed antigene studies or RNA-directed antisense and splice-switching studies.
The choice depends on whether the project aims to act at the DNA level or transcript level, the target region, delivery constraints, and the planned biological readout.
Yes. We support splice-junction and exon-focused PNA design for research programs evaluating exon skipping, exon inclusion, or isoform regulation.
Yes. PNA constructs can be supplied with functional groups such as peptides, PEG, fluorophores, biotin, or other project-relevant modifications.
Loading ......
